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transplant dysfunction. Although themajority of acute renal allograft rejection episodes can be adequately treat-
edwith glucocorticoid therapy, 25 to 30% of the rejection episode cannot be reversedwith glucocorticoids alone.
At present, the diagnosis of steroid resistance primarily relies on post-transplantation follow-up of clinical pa-
rameters reﬂecting renal allograft function. However, it remains difﬁcult to predict the response to the response
to antirejection treatment. Prediction of steroid resistance could prevent unnecessary exposure to high-dose cor-
ticosteroid therapy and avoid the development and progression of irreversible nephron. This impact of steroid-
refractory rejection on graft integrity stresses the need for tools to assess the response to AR treatment in an
early stage. Here, we discuss our current understanding of resistance to anti-rejection treatment with glucocor-
ticoids, and provide an overview of biomarkers for the detection and/or prediction of steroid resistance in kidney
transplantation.ejection
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Since the ﬁrst successful transplantation performed in 1954 [1], kid-
ney allograft transplantation has become the preferred renal replace-
ment therapy for patients suffering from end-stage renal disease. At
present,more than 36,500 kidney transplantations are performed annu-
ally in Europe and the United States [2,3]. Despite the success of renal
transplantation, approximately 40% of renal allografts fail within the
ﬁrst 10 years, and a shortage of donors hampers the number of trans-
plants performed each year [4,5]. These limitations stress the need to
improve long-term graft survival and prevent adverse graft outcome.
The occurrence of acute rejection (AR) is a dominant risk factor for
adverse graft outcome. AR is primarily a cellular immune response di-
rected againstmismatched donor antigens present on the cells of the al-
lograft [6,7], which generally occurs during the early post-transplant
period, with the highest risk in the ﬁrst 3 months. Reliable and timely
detection of AR episodes is important for the prevention of adverse
graft outcome. Diagnosis of AR episodes relies on clinical parameters
and histopathologic assessment of kidney biopsy samples [8–10].
Most patients who develop an AR episode are asymptomatic and pres-
ent only with an increase in serum creatinine levels as an indicator of
a decline in renal function [8]. The cause of graft dysfunction is deter-
mined based on nephropathologic criteria and histological assessment
of a renal allograft biopsy. The Banff classiﬁcation is used to identify
and designate the severity of rejection episodes on the basis of the site
and degree of inﬂammation in the transplanted kidney [9,10]. However,
once AR is diagnosed, it is difﬁcult to predict the response to anti-
rejection treatment based on clinical parameters and histopathologic
assessment. Availability of biomarkers could provide complementary
parameters for assessing the risk of adverse graft outcome. The present
reviewprovides an overviewof biomarkers of steroid resistant rejection
in kidney transplantation.
2. Impact of acute rejection on graft outcome
In the 1960s, AR was the most important cause of kidney transplant
loss. Only 40% of renal allograft recipients had a functioning graft at one
year after transplantation [11,12]. The introduction of immunosuppres-
sive medications and reﬁnement in treatment regimens during the fol-
lowing decades has reduced the incidence of AR from over 80% in the
1960s to below 15% nowadays [12,13]. Over the same period, the
short-term survival of kidney grafts has substantially improved, with
one-year graft survival rates in excess of 90% in current daily practice
[14,15]. Despite these advances in short-term outcome, long-term
graft outcome improved only marginally over the past two decades
[14–16]. Approximately 50% of grafts from deceased donors and 30%
of grafts from living donors fail within ten years after kidney transplan-
tation [17]. The graft attrition rates after the ﬁrst year are between 3%
and 5% annually. This is mainly due to death with a functioning graft
and chronic allograft failure [14,18,19].
Even after the introduction of immunosuppressive medication, AR
continues to be a primary cause of renal allograft failure. Approximately10% of all graft losses are directly caused by acute renal allograft rejection
[19]. In addition, the occurrence of AR correlates with a signiﬁcant reduc-
tion in long-term allograft survival [20–23]. Beside this association with
risk of graft loss, AR is also correlatedwith the development of chronic al-
lograft failure. Renal interstitial ﬁbrosis and tubular atrophy
(IFTA)—which was formerly known as chronic allograft nephropathy
(CAN)—is the most prevalent cause of chronic allograft failure after the
ﬁrst post-transplant year [12,19,24]. Analyses of factors related to the de-
velopment of IFTA revealed AR as one of the primary risk factors [25–27].
Although the incidence of AR has decreased during the last decades, the
negative impact of AR on subsequent development of IFTA and the risk
for chronic transplant failure have become more prominent [27].
Various parameters of AR determine the level of risk for adverse
graft outcome including the timing, recurrence, severity, and therapy
sensitivity of the AR episode [23]. Risk of graft failure increases as the
time between engraftment and occurrence of AR increases, and is
most pronounced with late AR episodes (occurring 3 months or more
after engraftment) [28–33]. Similarly, patients experiencing repeated
AR episodes are at greater risk of adverse graft outcome than those
with no or only one episode [34–37]. In addition, patients with acute
vascular rejection (Banff classiﬁcation grade II) have a higher risk of
graft failure compared to patients with acute tubulointerstitial rejection
(Banff classiﬁcation grade I) [38–40]. Furthermore, rejection episodes
unresponsive to AR treatment have been associated with increased
risk of allograft failure [40–42].
3. Treatment of acute renal allograft rejection
Immunosuppressive medication has become a cornerstone in the
transplantation ﬁeld. Investigation of the use of immunosuppression
for prevention of transplant rejection started in the early 1950s, when
Medawar and colleagues revealed that AR is driven by an immunologi-
cal process [43,44]. The ﬁrst tested therapies, i.e., total body irradiation
and adrenal cortical steroids [45,46], led to prolonged skin graft survival.
These early ﬁndings set the stage for the development of the current im-
munosuppressive drug therapies. Nowadays, almost all transplant re-
cipients are treated with immunosuppressive drugs to minimize the
chance of AR,which act by inhibiting the activation and/or effector func-
tions of T cells. Renal transplant recipients can still develop episodes of
acute allograft rejection despite optimization of human leukocyte anti-
gen (HLA) compatibility and application of induction therapy andmain-
tenance immunosuppression. Several therapeutic options are available
for the reversal of AR episodes.
3.1. Synthetic corticosteroids
Theﬁrst report on the use of immunosuppressive drugs for the treat-
ment of acute renal allograft rejection appeared in 1960 [47]. A young
female recipient of her mother's kidney developed multiple rejection
episodes, which were temporarily reversed with the synthetic cortico-
steroid drug prednisone. This case sparked the interest in synthetic glu-
cocorticoids (GCs) for both the prevention and treatment of AR
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allograft rejection could readily be reversed by temporarily adding
high doses of prednisone to the patients maintenance therapy [48].
Ten renal allograft recipients showed an essentially complete recovery
of their renal function. Based on these early ﬁndings, increased dosages
of the daily maintenance regimen with oral prednisone became the
main therapy for AR [49,50].
Treatment of ARwith high doses of oral prednisonewas found to po-
tentially induce toxic side effects, such as gastrointestinal hemorrhage
and increased susceptibility to infection. To prevent these complica-
tions, the treatment was switched from oral prednisone to intravenous
application ofmethylprednisolone during the early 1970s [49,50]. Com-
parison of the two regimens revealed that both GCs are equally success-
ful in reversing AR [51,52]. However, pulse therapy with intravenous
methylprednisolone is associatedwith fewer side effects than oral pred-
nisone therapy [49,52]. Nowadays, intravenous pulse therapy with
high-dose methylprednisolone has become the ﬁrst-line therapy for
AR in most medical centers.
3.2. Polyclonal and monoclonal antibodies
The ﬁrst report on antibody-based immunosuppression was by
Metchnikoff in 1899 [53]. His observations on the lymphocyte-
depleting activity of heterologous anti-lymphocyte serumwere validat-
ed in the 1960s [54–56]. These ﬁndings resulted in the introduction of
anti-thymocyte globulin (ATG), which represents serum-derived poly-
clonal antibodies obtained from horses or rabbits immunized with
human lymphocytes, as a treatment of allograft rejection [57–60]. ATG
therapy causes depletion of circulating T cells and other leukocytes
through various mechanisms, including antibody- and complement-
dependent lysis and the induction of apoptosis [61]. ATG is an effective
treatment of AR with high graft survival rates [62–64]. However, ATG
can induce complications, such as leukopenia, cytokine release syn-
drome, and viral infections [60,63]. Due to the risk of complications,Fig. 1.Mechanism of glucocorticoid signaling. GR, glucocortiATG is mainly used for the treatment of steroid-resistant AR and recur-
rent AR.
The development of cell-hybridization techniques provided the op-
portunity to produce monospeciﬁc antibodies [65]. The murine-
derivedMuromonab-CD3 (OKT3) is amonoclonal antibody based treat-
ment directed against the CD3 molecule, which is closely associated
with the T cell receptor (TCR). OKT3 therapy modulates the TCR,
resulting in the depletion of circulating T cells. OKT3 has been used as
primary treatment of AR as well as a rescue therapy of steroid-
resistant AR episodes [66–68]. Due to its lower efﬁcacy and higher inci-
dence of side effects compared to ATG treatment, OKT3 has been with-
drawn from the market and is no longer in clinical use [62,63,69,70].
4. Immunoregulatory effects of corticosteroids
The therapeutic effects of synthetic GCs for the treatment of acute
renal allograft rejection are attributed to their anti-inﬂammatory and
immunosuppressive effects. These protective effects on the allograft
are mainly obtained through direct and indirect regulation of
immune-related gene transcription. GCs regulate approximately 20%
of all genes expressed in leukocytes [71]. Depending on the cell type,
the estimated number of genes directly regulated by corticosteroids
lies between 10 and 100 [72]. However, the majority of inﬂammatory
genes are indirectly regulated through interference with transcription
factors and their co-activators. The major action of GCs is the suppres-
sion of inﬂammatory genes that are activated during AR, including
genes encoding for cytokines, chemokines, adhesion molecules, and in-
ﬂammatory enzymes (Fig. 1) [72–75]. Besides the downregulation of
pro-inﬂammatory genes, GCs increase the expression of anti-
inﬂammatory cytokines and transcription mediators (Fig. 1) [72,76].
In addition, glucocorticoid (GC) therapy can suppress AR through a va-
riety of othermechanisms, including the prevention of leukocytemigra-
tion, induction of cell death in lymphocytes, and effects on the growth
and lineage commitment of T cells [77–80].coid receptor; GRE, glucocorticoid responsive elements.
Fig. 2.Genomic and protein structure of thehuman glucocorticoid receptor. TheGR gene consists of 9 exons and is located in chromosome 5. Exon 1 is untranslated region, exon 2 codes for
the N-terminal domain (NTD), exons 3 and 4 code for the DNA-binding domain (DBD), and exons 5 to 9 code for the ligand-binding domain (LBD). The GR gene contains two terminal
exons 9 (exons 9α and 9β) alternatively spliced to produce the classic GRα and non-ligand binding GRβ.
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The actions of GCs are mediated by the intracellular glucocorticoid
receptor (GR), a ligand-dependent transcription factor of the nuclear re-
ceptor superfamily, which is ubiquitously expressed in most humanFig. 3. Corticosteroid signaling pathways. AP-1, activator protein-1; CREB, cyclic AMP-respo
glucocorticoid response elements; HDAC-2, histone deacetylase-2; Hsp, heat shock protein;
phosphatase 1; NF-κB, nuclear factor-κB; nGRE, negative glucocorticoid response elements.cells [73,78]. The genomic structure of the GR consists of 9 exons (Fig.
2) [75,81,82]. Alternative splicing in exon 9 generates two C-terminal
receptor isoforms, termed GRα and GRβ [81]. The predominantly
expressed GRα is activated by GC binding and mediates most of the
known immunomodulatory effects, whereas the GRβ isoform expressesnsive element-binding; FKBP, FK506-binding protein; GR, glucocorticoid receptor; GRE,
IκB, inhibitor of κB; MAP kinase, mitogen-activated protein kinase; MKP-1, MAP kinase
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pression of GRβ is induced by cytokines [86]. GRβ can exert a dominant
negative effect upon GRα-induced transcription. However, the func-
tional importance of the GRβ isoform has not yet been determined.
The GR protein structure consists of three domains (Fig. 2): an N-
terminal domain (NTD) that directs target gene activation and the inter-
action with other transcription factors; a central DNA-binding domain
(DBD), responsible for binding with glucocorticoid response elements
(GRE) in the promoter region of target genes; and a ligand-binding do-
main (LBD), which contains speciﬁc GC- and heat shock protein (Hsp)
binding sites [87–90].
After administration, GCs diffuse across the cell membrane and bind
to the cytoplasmic GR. In its ligand-free state, the cytoplasmic GRα is as-
sociatedwith an inhibitory complex, inwhich twoHsp90molecules and
one molecule each of Hsp70 and FK506-binding protein 52 (FKBP52)
are included (Fig. 3) [78,82,91]. This association stabilizes the
hormone-responsive form of the receptor and inhibits nuclear localiza-
tion. Upon ligand-induced activation, the GR undergoes conformational
changes and dissociates from the molecular chaperone proteins [72,91,
92], which enables rapid translocation of the GC-GR complex to the nu-
cleus. In this location the complex regulates gene transcription through
direct and indirect signaling pathways (Fig. 3).
GR dimers bind via two zinc ﬁnger motifs in the DBD to GRE in the
promoter region of target genes [93–95]. To initiate gene transcription,
the GR uses transcriptional activation domains located in the NTD and
LBD. The GR interacts with the promoter region and recruits transcrip-
tional co-activators and basal transcription machinery to the transcrip-
tion start site [82,91]. This group of co-activators includes steroid
receptor co-activator-1 (SRC-1), CREB-binding protein (CBP), and GR-
interacting protein 1 (GRP-1), which induce histone acetylation and
subsequent transcription of anti-inﬂammatory genes (trans-activation)
[72,76]. Less commonly, the GC-GR complex interacts with negative
GRE (nGRE) resulting in the repression of pro-inﬂammatory genes
that contain GR-binding sites (cis-repression) [91,92].
The major action of corticosteroids is the indirect suppression
(trans-repression) of pro-inﬂammatory genes that are activated during
AR [72–75]. The GC-GR complex interferes with activating transcription
factors, such as nuclear factor-κB (NF-κB), activator protein-1 (AP-1),
and cyclic AMP-responsive element-binding (CREB), and the transcrip-
tional co-activator molecules of these transcription factors. In addition,
the GC-GR increases the transcription of inhibitor of κB (IκB) and MAP
kinase phosphatase (MKP)-1, which inhibit NF-κB and mitogen-
activated protein (MAP) kinase, respectively [73,78]. Furthermore, the
GC-GR complex recruits histone deacetylase (HDAC)-2 to the activated
inﬂammatory gene complex, resulting in deacetylation of nuclear his-
tones and inhibition of pro-inﬂammatory gene transcription (Fig. 3)
[72,73,75]. The signaling pathways of the GC-GR complex inhibit the
transcription of pro-inﬂammatory molecules, including cytokines,
chemokines, adhesion molecules, inﬂammatory enzymes, and recep-
tors. Alterations in the molecular mechanisms of GR signaling may
lead to steroid resistance.5. Steroid resistance
The majority of acute renal allograft rejection episodes can be ade-
quately treated with high-dose corticosteroids. However, in approxi-
mately 25 to 30% of the patients the rejection episode cannot be
reversed with corticosteroid therapy alone [42,96–101]. Similarly,
poor or no response to steroid therapy for AR reversal also occurs in re-
cipients of other solid organ transplants, including liver, lung and cardi-
ac allografts [102–104]. In such cases of steroid resistance, the patient
requires more rigorous immunotherapy to reverse the AR episode.
Renal allograft recipients with steroid-refractory rejection are generally
treated with ATG, which results in a salvage rate of 70 to 90% [70,105–
107].Diagnosis of steroid resistance primarily relies on post-
transplantation follow-up of clinical parameters reﬂecting renal allo-
graft function. An AR episode is considered steroid resistant when the
patient's serum creatinine levels do not return to within 120% of the
pre-rejection baseline value after pulse therapy with corticosteroids
within 14 days after the start of the steroid therapy [7,107–109]. At
that point, ATG treatment is generally required. The ﬁrst few days
after the start of the steroid treatment are crucial. Analysis of creatinine
courses of steroid-resistant and steroid-responsive cases revealed that
the minimal time period for assessment of the response to steroids is
ﬁve days after initiation of the pulse therapy [96]. Changes in serum cre-
atinine levels were similar between patients with steroid responsive
and steroid resistant AR until day 5, at which time the responders
showed a signiﬁcant decrease in serum creatinine, while the creatinine
level of non-responders remained high. This 5-day period is also the av-
erage time delay used by clinicians before considering a rejection as
being steroid resistant [110]. Incomplete restoration of graft function
in steroid resistant rejectionmay lead to progression of chronic damage
to the graft and has a detrimental effect on graft outcome [40–42,98,
111].
6. Assessment of risk for steroid resistance
Prediction of steroid resistance at the time of biopsy could prevent
unnecessary exposure to high-dose corticosteroid therapy.More impor-
tantly, the development and progression of irreversible nephron loss
during the period that steroid resistant AR is undertreated with steroids
alone could be avoided. This impact of steroid-refractory rejection on
graft integrity stresses the need for tools to assess the response to AR
treatment in an early stage.
6.1. Clinical and pathologic indicators of steroid resistant rejection
At present, clinical parameters and histopathologic assessment of
kidney biopsies remain the golden standard for evaluating short- and
long-term graft outcome. Several parameters have been associated
with response to steroid treatment. Acute vascular rejection is related
to resistance to high-dose steroid therapy and a subsequent higher
chance of graft failure [108,112,113]. In addition, unresponsiveness to
steroid therapy has been associated with the presence of mononuclear
cells at endothelial cells of large and small vessels in the graft [108]. An-
other aspect associated with steroid resistance is the presence of an im-
mune response directed against the microvasculature. Patients with
moderate to severe microvascular destruction respond less adequately
to steroid therapy compared to patients with only mild destruction of
the microvascular endothelium [113]. Steroid-refractory AR has been
associated with more extensive leukocyte inﬁltration into the
peritubular capillaries (PTC) [113]. Circulating leukocytes target HLA
molecules expressed on the PTC, which results into cellular rejection.
In addition, the HLA molecules can also be targeted by donor-speciﬁc
antibodies, leading to local complement activation and humoral rejec-
tion. The activation of the complement cascade leads to the formation
of complement degradation factor C4d, which can covalently bind to
the PTC endothelium [114]. C4d deposition in PTC has been associated
with steroid resistance [115–118], although this association could not
be conﬁrmed in a recent study [119].
6.2. Prognostic biomarkers for steroid resistant rejection
It remains difﬁcult to predict the risk of graft loss and the response to
anti-rejection treatment on basis of histopathologic assessment and
clinical parameters. Biomarkers for molecular and cellular mechanisms
involved in graft survival andmedication responsiveness could provide
complementary parameters for assessing the risk of adverse graft
outcome.
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Indeed, expression levels of various markers, particularly those of
allograft-inﬁltrating inﬂammatory cell types, were found to be informa-
tive with respect to therapy response. Analyses of AR biopsies obtained
from kidney transplant recipients have provided insight into the lym-
phocyte populations that are associatedwith poor graft outcome. Resis-
tance to GCs has been associated with increased expression of cytotoxic
T lymphocyte-, natural killer (NK) cell-, B lymphocyte-, and macro-
phage signatures [99,101,120–128].
6.2.1.1. Cytotoxic T lymphocytes and NK cells. The ﬁrst immune compo-
nent linked with resistance to anti-rejection treatment and graft out-
come was the presence of T lymphocytes. The extent of CD8+ T cells
inﬁltration within the allograft was correlated with response to AR
treatment with GCs [123]. These ﬁndings are in line with data from
gene expression studies in rejection biopsies of renal allografts in chil-
dren, which revealed increased mRNA expression levels of cytotoxic T
cell and NK cell markers in steroid-refractory AR samples [99]. Further-
more, relatively high FasLmRNA expression [101] and dense granulysin
staining [124] in renal allograft biopsies, aswell as low FoxP3 expression
in urinary sediments [125], have all been described to be associated
with steroid resistant rejection.
6.2.1.2. B lymphocytes. The extent of B cell inﬁltrationwithin the renal al-
lograft was shown to discriminate between steroid resistant and steroid
response AR episodes. Patients with steroid-refractory AR expressed in-
creased intragraft levels of the B cellmarker CD20 and B-lymphocyte as-
sociated immunoglobulins [99,120,121]. In line with these ﬁndings,
immunostainings for CD20 revealed signiﬁcant differences in the level
of B cell inﬁltrationduring AR,which correlatedwith response to steroid
therapy and long-term graft outcome [99,120]. Besides their essential
role in humoral immune response, inﬁltrating B cells may function as
antigen presenting cells and amplify the alloimmune response by
donor-speciﬁc T cells. However, more recent studies failed to conﬁrm
that the presence of intragraft B cells is related to therapy response
and/or graft function after rejection [100,109,129,130].
6.2.1.3. Macrophages.Macrophages derived from the transplant recipi-
ent are an important aspect of the immune inﬁltrate during AR [122,
126–128]. Macrophage inﬁltration within the kidney transplant has
been related with response to GC therapy. Immunostainings for CD68
revealed the presence of intraglomerular and interstitial macrophages
during AR as prognostic markers for steroid resistance and graft out-
come [122,126–128,131]. In addition, macrophage inﬁltration has
been shown to associate with intimal arteritis [132] and C4d deposition
in PTC [133], which on themselves represent risk factors for resistance
to anti-rejection treatment.
6.2.2. Challenges for biomarker identiﬁcation in clinical context
Even though various immunemarkers have been proposed as prog-
nostic biomarkers for graft outcome, clinical interpretation of these
ﬁndings has proven difﬁcult. The interpretation and validation of pub-
lished data is complicated by diversity in clinical endpoint deﬁnitions
and patient cohort characteristics. The deﬁnition of steroid resistance
varies widely between studies, and reported cases of steroid-
refractory rejection are frequently poorly deﬁned [99,101,120,122–
128]. Other aspects that inﬂuence the inter-study reproducibility of bio-
markers are differences in patient cohort characteristics, such as type of
immune suppression and the time between transplantation and AR, as
well as the techniques used for sample processing and expression anal-
ysis. As a result the prognostic value of proposed immune biomarkers
for steroid-refractory AR could not be veriﬁed in later studies [100,
109,129,130].
In an attempt to overcome some of these challenges, we evaluated
the expression levels of a broad panel of immunological markers within
renal allografts with steroid responsive or steroid resistant AR [134],including the previously reported markers associated with response to
steroid therapy [99,101,120–128]. The selected panel reﬂected the full
immune repertoire thatmay be present in the grafts. In addition, a com-
bination of strict inclusion criteria, stringent clinical endpoint deﬁni-
tions, and quality controls for sample processing and expression
assays were employed to ensure reliable and sensitive identiﬁcation of
prognostic biomarkers for response to GCs. The study showed that a
combination of T cell activation markers CD25:CD3ε ratio and lympho-
cyte activation gene-3 (LAG-3) offers an improved prognostic value for
assessing steroid response, compared to conventional clinical parame-
ters and histopathologic assessment. These two signal transduction
molecules are involved in the regulation of T cells: CD25, the α-
subunit of the IL-2 receptor (IL-2R), is an important regulator of T cell
survival and proliferation [135,136]; while the activation-induced
LAG-3 is involved in the negative regulation of homeostasis and T cell
function [137,138]. High expression of cytotoxic T cells has been associ-
ated with resistance to steroid treatment of acute renal allograft rejec-
tion [123]. In addition, T cell characteristics, through disparities in IL-2
responses, have been correlated with steroid resistance [139–141].
The ﬁndings described in the previous sections suggest that steroid
resistance may reside in speciﬁc lymphocyte populations, with activat-
ed T cell populations as the prime candidate. However, the prognostic
value of immune biomarkers is hampered by molecular heterogeneity
among kidney biopsy samples with AR. This observation may be a re-
ﬂection of the complexity of the mechanisms involved in response to
steroid therapy.6.2.3. Non-immunological biomarkers
A relatively novel ﬁnding is the link between zinc regulation and re-
sistance to anti-rejection treatment with steroids. Relatively high
intragraft expression of metallothioneins (MT) and tissue inhibitor of
metalloproteinase-1 (TIMP1) during acute renal allograft rejection is as-
sociatedwith steroid resistance [142]. Sevenmembers of theMT-1 gene
family were expressed to a signiﬁcantly higher extent in steroid-
refractory AR. MT expression was mainly detected in activated macro-
phages and tubular epithelial cells within the kidney. These ﬁndings
are in line with ﬁndings in lung allograft recipients, where increased
percentages of MT-positive macrophages were found in transbronchial
biopsy samples of lung allograft recipients with steroid-refractory AR
[143]. MT are cysteine-rich proteins involved in the homeostasis of bio-
logically essentialmetals, ofwhich the regulation of zinc ions is themost
important [93,144–147]. By functioning as a zinc-donor or zinc-
acceptor, MT can control cellular zinc distribution [93,144]. Increased
intragraft MT expression may lead to removal of zinc ions that are nor-
mally used in GC signaling. The binding of the activated GC-GR complex
to GREs relies on two zinc ﬁnger motifs located in the DBD [93–95]. In-
creased MT levels may lead to removal of zinc ions that are normally
complexed in the zinc ﬁnger motifs [148,149], thereby preventing GR
binding to GREs and inhibiting the immunomodulatory effects of
trans-activation and cis-repression (Fig. 4). Another GC signaling path-
way that may be affected by MT is the zinc-dependent recruitment of
HDAC-2 by the GC-GR complex [72,73,75]. Increased expression of MT
may lead to inhibition of the anti-inﬂammatory effects of this process
(Fig. 4). Interestingly, several studies in the oncological research ﬁeld
have also demonstrated that elevated MT expression is related to treat-
ment resistance [150–152].
TIMP1 has been identiﬁed as an endogenous inhibitor of matrix me-
talloproteinases (MMP) [153]. TIMP1 inhibits MMP activity through co-
ordination of the zinc ions of the MMP active site by the conserved
cysteine residues in its N- and C-terminal domains [154,155]. Similar
to MT, TIMP1 may diminish the zinc-requiring anti-inﬂammatory ef-
fects of the GR through regulation of the intracellular zinc concentra-
tions (Fig. 4). In addition, more recent studies have implicated TIMP-1
in the regulation of cell growth and apoptosis [155], which may inﬂu-
ence the effects of GC signaling.
Fig. 4. Effect of zinc-regulatingmolecules on corticosteroid signaling. GR, glucocorticoid receptor; GRE, glucocorticoid response elements; HDAC-2, histone deacetylase-2; nGRE, negative
glucocorticoid response elements.
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Fig. 5. Schematic overview of the NR3C1 SNPs associated with enhanced (N363S and BclI)
or reduced (ER22/23EK and GR-9β) sensitivity to glucocorticoids.
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cellular signaling pathways, which include NF-κB andMAP kinase path-
ways [156–158]. Differences in F2R may inﬂuence the pro- and anti-
inﬂammatory effects of GCs [142]. Further research will be needed to
unravel themechanisms throughwhich F2R affects the response to ste-
roid therapy.
6.2.4. Combination of immune- and non-immune biomarkers
Even though the biomarkers described in the previous sections pro-
vide a strong prognostic value for predicting a patient's response to GC
therapy, no single biomarker has been able to predict the response to
steroid treatment with both high sensitivity and high speciﬁcity. This
restricted power of singlemarkers is most likely caused by the presence
of multiple mechanisms underlying steroid resistance, which is
reﬂected by the observed heterogeneity in transcriptional regulation
among AR biopsy samples [99,134].
Combination of biomarkers in amultivariate predictionmodel could
enhance sensitivity and speciﬁcity, and facilitate risk assessment of ste-
roid resistance in patients suffering fromAR.Multivariate analysis of the
proposed biomarkers revealed a prediction model that contains both
immune (CD25:CD3ε ratio, LAG-3) and non-immune (MT-1, TIMP1,
F2R) biomarkers as independent covariates [142]. This multivariate
model offers a superior prognostic value for assessing responsiveness
to GC therapy compared to both conventional clinical and histopatho-
logic indicators as well as single biomarkers.
6.2.5. Glucocorticoid receptor expression
As described in a previous section, the anti-inﬂammatory and immu-
nosuppressive actions of GCs aremediated by the ligand-dependent GR.
Consequently, differences in response to treatmentwith GCsmay be ex-
plained by variations in GR expression.
Decreased GR expression has been implicated as a cause of steroid
resistance in a wide variety of diseases, including nephrotic syndrome
[159], acute lymphoblastic leukemia [160], and asthma [161]. The ob-
served differences in GR expression between responders and nonre-
sponders might be a reﬂection of varying levels of GR autoregulation.
This process, in which the presence of GCs can lead to down-
regulation of the steady-state expression levels of GR, has been ob-
served in both cell lines and tissues [162–166]. However, more recent
studies were unable to conﬁrm this as the sole cause of GC resistance
[167], indicating that other mechanismsmay be involved in the varying
GR expression levels. Response to GCs might also be related to the ratioof primary GRα and cytokine-induced GRβ isoforms (see Section 4.1)
[81,86]. Upregulation of GRβ levels has been associated with resistance
to steroid therapy in different diseases, such as asthma [168,169], in-
ﬂammatory bowel disease (IBD) [170], and ulcerative colitis [171,172].
GRβ's dominant negative inhibition of GRα-induced gene transcription
may provide enhanced resistance to the effects of GCs. However, the
role of GRβ in steroid resistance remains controversial, as other studies
were unable to conﬁrm a link between GRβ expression levels and re-
sponsiveness to GCs [173].
In addition to GR expression levels, differences in treatment re-
sponse may also be explained by genetic variability. Mutations in the
GR gene (NR3C1, nuclear receptor subfamily 3, group C, member
1) can affect the functionality of the GR and result in steroid resistance.
Although GR mutations leading to loss of function and generalized GC
resistance are rare [174], single nucleotide polymorphisms (SNPs) in
NR3C1 may alter the GC binding afﬁnity or the downstream signaling
of the receptor [175,176]. A large number of NR3C1 SNPs have been de-
scribed (see the National Center for Biotechnology Information (NCBI)
dbSNP database), but only a few polymorphisms are functionally rele-
vant (reviewed in [177]). The two adjacent and linked ER22/23EK
(rs6189/rs6190) polymorphisms are located in the NTD of the GR (Fig.
5). The resulting amino acid substitution can affect the receptor's
trans-activational and trans-repressional activity on target genes
[177]. The ER22/23EK polymorphisms have been associated with re-
duced sensitivity to GCs [178–180], although the responsiveness of
R22/23K carriers may vary, ranging from asymptomatic to severely GC
resistant [181]. Similarly, the GR-9β (rs6198) polymorphism has been
correlated with GC resistance in rheumatoid arthritis [182]. This SNP,
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bilizing effect on the mRNA of the GRβ isoform, which subsequently
leads to enhanced expression of the inactive GRβ protein.
In contrast, two other NR3C1 SNPs have been associated with en-
hanced sensitivity to GCs. One of themost common functional polymor-
phisms (allele frequency of 35%) in NR3C1 is the BclI (rs41423247)
polymorphism [179,183]. This SNP consists of a C N G nucleotide substi-
tution, 646 nucleotides downstream from exon 2 (Fig. 5). The BclI poly-
morphism is associated with hypersensitivity to GCs in both
heterozygous and homozygous carriers of the G allele. A signiﬁcantly
higher frequency of BclI mutated genotype was observed in GC respon-
sive patients with IBD compared to nonresponder IBD patients [91]. The
N363S (rs6195) polymorphism is located in exon 2 of the NR3C1 gene,
which corresponds with the N-terminal domain of the GR (Figs. 2 and
5). This mutation was shown to increase the receptors trans-activating
capacity [180]. The N363S polymorphism is associated with increased
sensitivity to GCs, as was shown by increased cortisol suppression
after dexamethasone suppression tests in a group of elderly individuals
[184].
While scientists in various disease ﬁelds have been interest in the
potential correlation between GR expression and the response to GCs,
very little is known about this relationship in the transplantation ﬁeld.
Recent data from our group revealed no correlation between steroid-
refractory AR and the GR. Both the NR3C1 genotype distribution and
GR expression levels in the renal allograft were similar between kidney
transplant recipients with response and resistance to GC treatment of
AR (unpublished data). Further studies will be needed to conﬁrm the
role of the GR in transplant recipients with GC resistance.
7. Clinical implications
The data discussed in this review demonstrate that steroid resis-
tance is a complex andmultifactorial condition, inwhich both immuno-
logical and non-immunological factors can be involved. Investigations
of immune-related biomarkers revealed that both T cells and macro-
phages play an important role in the response to steroid therapy. Com-
bined, these ﬁndings indicate that steroid resistance resides in speciﬁc
cell populations. This may guide the therapeutic approaches for treat-
ment of steroid-refractory AR episodes. Furthermore, Zinc regulation
may play a role in the response to steroid therapy during AR. Kidney
transplant recipients who express high intragraft levels of MT and
TIMP1 during AR might beneﬁt from extra zinc intake for optimal GC
signaling.
The presence of multiple mechanisms underlying steroid resistance
probably accounts for the restricted predictive power of single markers.
Molecular heterogeneity among biopsy samples may explain the difﬁ-
culties in validating the prognostic value of previously proposed bio-
markers for steroid resistance. In addition, it demonstrates the
importance of using internal and external validation techniques to ver-
ify the robustness of potential biomarkers.
We found that a multivariate prediction model, containing bio-
markers related to different aspects of GC signaling, offers a superior
prognostic value for assessing steroid response compared to conven-
tional clinical parameters and histopathologic assessment, and to single
biomarkers [142]. Such a multivariate approach could identify patients
with insufﬁcient response to anti-rejection treatment with GCs, who
would beneﬁt from immediate ATG treatment. Availability of a multi-
variate biomarker model in the clinic may lead to reduced exposure to
high-dose corticosteroid therapy. More importantly, it may help avoid
the development and progression of irreversible nephron loss during
the period that steroid-refractory AR is undertreated with steroids
alone. In addition, multivariate models provide insight into the causa-
tive mechanisms in steroid-refractory AR episodes, which may guide
the development of novel therapeutic approaches. Our recently pro-
posed multivariate model, which includes T cell activation markers
and zinc regulating molecules as independent covariates, does notreach 100% speciﬁcity and sensitivity for the prediction of steroid-
refractory AR. This suggests that additional, yet unidentiﬁed factors in-
ﬂuence the response to high-dose steroid treatment of acute renal allo-
graft rejection.
8. Future perspectives
8.1. Validation of the prognostic value of biomarkers
An essential requirement in biomarker discovery is validation and
veriﬁcation of the predictive value of proposed biomarkers. Validation
techniques, such as cross-validation and the use of (unrelated) discov-
ery and validation cohorts, ensure accurate and appropriate data collec-
tion and verify the clinical usefulness of proposed biomarkers. In
addition, the prognostic value of the biomarkers should be conﬁrmed
in a prospective study before they can be introduced into the clinic.
8.2. MicroRNA expression as a novel biomarker for response to steroid
therapy
A relatively novel target for the identiﬁcation of potentially informa-
tive biomarkers is the expression of microRNA transcripts. MicroRNAs
are a class of small, non-coding RNAmolecules that negatively regulate
mRNA expression by degradation or translational repression [185,186].
Since the initial discovery in the early 1990s, over 1000microRNAs have
been identiﬁed. It is estimated that expression ofmore than one third of
all genes is regulated by microRNAs [187,188]. In recent years,
microRNAs have gained interest for their involvement in hematopoiesis
and immune cell function [189–192], and for their role in allograft rejec-
tion [193–195]. Because of their relatively stable expression,microRNAs
are emerging as potential biomarkers. Analysis of microRNA expression
proﬁles in renal biopsies may lead to the identiﬁcation of novel prog-
nostic biomarkers for the outcome of acute renal allograft rejection.
8.3. Non-invasive methods for monitoring of graft outcome
Although evaluation of renal biopsies remains the gold standard for
the diagnosis of graft outcome, its usefulness is slightly limited by the
invasive nature of the biopsy procedure. Due to the associated risk of
procedural complications, renal biopsies are mainly performed on clin-
ical indication [7,196]. An alternative to intragraft assessment could be
the use of less invasive or non-invasive sources of patient material,
such as peripheral blood and urine samples. Identiﬁcation of molecular
markers in blood and urine may provide means to monitor graft func-
tion more frequently, which could lead to earlier detection of graft dys-
function and timely intervention of the immune process. However, it is
not yet clearwhether expression levels ofmolecularmarkers in blood or
urine are as reliable as measurements of molecular markers in renal
biopsies.
Peripheral blood samplesmay provide a suitablemeans to assess if a
renal allograft recipient is responsive to steroid therapy. In vitro tests
with peripheral blood mononuclear cells (PBMC) exposed to GCs have
been used to correlate gene expression proﬁles with clinical disorders,
including steroid responsiveness [74,142,197–199]. However, the ex-
perimental design of these in vitro tests varied between studies, and
the ﬁndings could not always be reproduced. Further studies will be
needed to conﬁrm if in vitro cultures of patient PBMC represent a useful
indicator of the patient's response to steroid treatment in vivo.
9. Conclusion
Resistance to steroid therapy is a complex and multifactorial condi-
tion, in which both immunological and non-immunological factors can
be involved. The response to high-dose corticosteroid therapy for the
treatment of acute renal allograft rejection correlates with the expres-
sion level and characteristics of T cells and macrophages inﬁltrating
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resides in speciﬁc cell populations and is not a feature of all lympho-
cytes. Zinc regulation and drug metabolism may play a role in the re-
sponse to steroid therapy during acute renal allograft rejection.
Increased expression of zinc-regulating molecules may diminish the
zinc-requiring anti-inﬂammatory effects of corticosteroid therapy.
Therefore, kidney transplant recipients may beneﬁt from additional
zinc intake to optimize GC signaling. A multivariate prediction model,
containing biomarkers related to different aspects of GC signaling, offers
the best prognostic value for assessing steroid response. It is expected
that the use of such a model contributes in clinical risk assessment of
steroid resistance and helps in applying more individualized anti-
rejection therapy.
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